433 related articles for article (PubMed ID: 22923433)
1. Genome sequencing identifies a basis for everolimus sensitivity.
Iyer G; Hanrahan AJ; Milowsky MI; Al-Ahmadie H; Scott SN; Janakiraman M; Pirun M; Sander C; Socci ND; Ostrovnaya I; Viale A; Heguy A; Peng L; Chan TA; Bochner B; Bajorin DF; Berger MF; Taylor BS; Solit DB
Science; 2012 Oct; 338(6104):221. PubMed ID: 22923433
[TBL] [Abstract][Full Text] [Related]
2. Response and acquired resistance to everolimus in anaplastic thyroid cancer.
Wagle N; Grabiner BC; Van Allen EM; Amin-Mansour A; Taylor-Weiner A; Rosenberg M; Gray N; Barletta JA; Guo Y; Swanson SJ; Ruan DT; Hanna GJ; Haddad RI; Getz G; Kwiatkowski DJ; Carter SL; Sabatini DM; Jänne PA; Garraway LA; Lorch JH
N Engl J Med; 2014 Oct; 371(15):1426-33. PubMed ID: 25295501
[TBL] [Abstract][Full Text] [Related]
3. Everolimus tablets for patients with subependymal giant cell astrocytoma.
Turner SG; Peters KB; Vredenburgh JJ; Desjardins A; Friedman HS; Reardon DA
Expert Opin Pharmacother; 2011 Oct; 12(14):2265-9. PubMed ID: 21806479
[TBL] [Abstract][Full Text] [Related]
4. Next-generation sequencing reveals somatic mutations that confer exceptional response to everolimus.
Lim SM; Park HS; Kim S; Kim S; Ali SM; Greenbowe JR; Yang IS; Kwon NJ; Lee JL; Ryu MH; Ahn JH; Lee J; Lee MG; Kim HS; Kim H; Kim HR; Moon YW; Chung HC; Kim JH; Kang YK; Cho BC
Oncotarget; 2016 Mar; 7(9):10547-56. PubMed ID: 26859683
[TBL] [Abstract][Full Text] [Related]
5. Words of wisdom: Re: Genome sequencing identifies a basis for everolimus sensitivity.
Zlotta AR
Eur Urol; 2013 Sep; 64(3):516. PubMed ID: 23915465
[No Abstract] [Full Text] [Related]
6. Differentiating the mTOR inhibitors everolimus and sirolimus in the treatment of tuberous sclerosis complex.
MacKeigan JP; Krueger DA
Neuro Oncol; 2015 Dec; 17(12):1550-9. PubMed ID: 26289591
[TBL] [Abstract][Full Text] [Related]
7. Biomedicine. Rare cancer successes spawn 'exceptional' research efforts.
Kaiser J
Science; 2013 Apr; 340(6130):263. PubMed ID: 23599454
[No Abstract] [Full Text] [Related]
8. PTEN expression and mutations in TSC1, TSC2 and MTOR are associated with response to rapalogs in patients with renal cell carcinoma.
Roldan-Romero JM; Beuselinck B; Santos M; Rodriguez-Moreno JF; Lanillos J; Calsina B; Gutierrez A; Tang K; Lainez N; Puente J; Castellano D; Esteban E; Climent MA; Arranz JA; Albersen M; Oudard S; Couchy G; Caleiras E; Montero-Conde C; Cascón A; Robledo M; Rodríguez-Antona C; García-Donas J;
Int J Cancer; 2020 Mar; 146(5):1435-1444. PubMed ID: 31335987
[TBL] [Abstract][Full Text] [Related]
9. Phase II study of everolimus in metastatic urothelial cancer.
Milowsky MI; Iyer G; Regazzi AM; Al-Ahmadie H; Gerst SR; Ostrovnaya I; Gellert LL; Kaplan R; Garcia-Grossman IR; Pendse D; Balar AV; Flaherty AM; Trout A; Solit DB; Bajorin DF
BJU Int; 2013 Aug; 112(4):462-70. PubMed ID: 23551593
[TBL] [Abstract][Full Text] [Related]
10. Clinical activity of mTOR inhibition with sirolimus in malignant perivascular epithelioid cell tumors: targeting the pathogenic activation of mTORC1 in tumors.
Wagner AJ; Malinowska-Kolodziej I; Morgan JA; Qin W; Fletcher CD; Vena N; Ligon AH; Antonescu CR; Ramaiya NH; Demetri GD; Kwiatkowski DJ; Maki RG
J Clin Oncol; 2010 Feb; 28(5):835-40. PubMed ID: 20048174
[TBL] [Abstract][Full Text] [Related]
11. TSC1 loss synergizes with KRAS activation in lung cancer development in the mouse and confers rapamycin sensitivity.
Liang MC; Ma J; Chen L; Kozlowski P; Qin W; Li D; Goto J; Shimamura T; Hayes DN; Meyerson M; Kwiatkowski DJ; Wong KK
Oncogene; 2010 Mar; 29(11):1588-97. PubMed ID: 19966866
[TBL] [Abstract][Full Text] [Related]
12. Equivalent benefit of mTORC1 blockade and combined PI3K-mTOR blockade in a mouse model of tuberous sclerosis.
Pollizzi K; Malinowska-Kolodziej I; Stumm M; Lane H; Kwiatkowski D
Mol Cancer; 2009 Jun; 8():38. PubMed ID: 19527517
[TBL] [Abstract][Full Text] [Related]
13. The role of mTOR in bladder cancer.
Gust KM; So AI
Cancer Biol Ther; 2009 Dec; 8(24):2348-50. PubMed ID: 19949304
[No Abstract] [Full Text] [Related]
14. A Phase II trial of the oral mTOR inhibitor everolimus in relapsed Hodgkin lymphoma.
Johnston PB; Inwards DJ; Colgan JP; Laplant BR; Kabat BF; Habermann TM; Micallef IN; Porrata LF; Ansell SM; Reeder CB; Roy V; Witzig TE
Am J Hematol; 2010 May; 85(5):320-4. PubMed ID: 20229590
[TBL] [Abstract][Full Text] [Related]
15. mTOR: A pathogenic signaling pathway in developmental brain malformations.
Crino PB
Trends Mol Med; 2011 Dec; 17(12):734-42. PubMed ID: 21890410
[TBL] [Abstract][Full Text] [Related]
16. Everolimus improves neuropsychiatric symptoms in a patient with tuberous sclerosis carrying a novel TSC2 mutation.
Hwang SK; Lee JH; Yang JE; Lim CS; Lee JA; Lee YS; Lee K; Kaang BK
Mol Brain; 2016 May; 9(1):56. PubMed ID: 27216612
[TBL] [Abstract][Full Text] [Related]
17. Activating mTOR mutations in a patient with an extraordinary response on a phase I trial of everolimus and pazopanib.
Wagle N; Grabiner BC; Van Allen EM; Hodis E; Jacobus S; Supko JG; Stewart M; Choueiri TK; Gandhi L; Cleary JM; Elfiky AA; Taplin ME; Stack EC; Signoretti S; Loda M; Shapiro GI; Sabatini DM; Lander ES; Gabriel SB; Kantoff PW; Garraway LA; Rosenberg JE
Cancer Discov; 2014 May; 4(5):546-53. PubMed ID: 24625776
[TBL] [Abstract][Full Text] [Related]
18. Extrarenal perivascular epithelioid cell tumors (PEComas) respond to mTOR inhibition: clinical and molecular correlates.
Dickson MA; Schwartz GK; Antonescu CR; Kwiatkowski DJ; Malinowska IA
Int J Cancer; 2013 Apr; 132(7):1711-7. PubMed ID: 22927055
[TBL] [Abstract][Full Text] [Related]
19. PIK3CA/PTEN mutations and Akt activation as markers of sensitivity to allosteric mTOR inhibitors.
Meric-Bernstam F; Akcakanat A; Chen H; Do KA; Sangai T; Adkins F; Gonzalez-Angulo AM; Rashid A; Crosby K; Dong M; Phan AT; Wolff RA; Gupta S; Mills GB; Yao J
Clin Cancer Res; 2012 Mar; 18(6):1777-89. PubMed ID: 22422409
[TBL] [Abstract][Full Text] [Related]
20. Stromal liver kinase B1 [STK11] signaling loss induces oviductal adenomas and endometrial cancer by activating mammalian Target of Rapamycin Complex 1.
Tanwar PS; Kaneko-Tarui T; Zhang L; Tanaka Y; Crum CP; Teixeira JM
PLoS Genet; 2012; 8(8):e1002906. PubMed ID: 22916036
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]